Wenlin Shao
About
Wenlin Shao is a scholar working on Molecular Biology, Oncology and Immunology.
According to data from OpenAlex, Wenlin Shao has authored 27 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 5 papers in Immunology. Recurrent topics in Wenlin Shao's work include Histone Deacetylase Inhibitors Research (5 papers), Cancer-related Molecular Pathways (5 papers) and Adenosine and Purinergic Signaling (4 papers). Wenlin Shao is often cited by papers focused on Histone Deacetylase Inhibitors Research (5 papers), Cancer-related Molecular Pathways (5 papers) and Adenosine and Purinergic Signaling (4 papers). Wenlin Shao collaborates with scholars based in United States, China and Australia. Wenlin Shao's co-authors include Myles Brown, X. Shirley Liu, Jérôme Eeckhoute, Eli V. Hestermann, Pamela A. Silver, Alexander S. Brodsky, Jason S. Carroll, Timothy R. Geistlinger, Wei Li and Clifford A. Meyer and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Genes & Development.
In The Last Decade
Wenlin Shao
26 papers receiving 2.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Wenlin Shao United States | 14 | 1.5k | 754 | 480 | 238 | 178 | 27 | 2.0k | ||
| Meei‐Huey Jeng United States | 19 | 1.2k 0.8× | 728 1.0× | 565 1.2× | 265 1.1× | 206 1.2× | 30 | 1.9k | ||
| Erika Krasnickas Keeton United States | 10 | 1.6k 1.1× | 935 1.2× | 589 1.2× | 357 1.5× | 143 0.8× | 19 | 2.3k | ||
| Cem Elbi United States | 23 | 1.4k 0.9× | 397 0.5× | 462 1.0× | 219 0.9× | 197 1.1× | 38 | 2.2k | ||
| Jean-Marc Schlaeppi Switzerland | 18 | 1.1k 0.7× | 475 0.6× | 561 1.2× | 377 1.6× | 116 0.7× | 25 | 1.9k | ||
| Hema Parmar United States | 13 | 656 0.4× | 461 0.6× | 591 1.2× | 198 0.8× | 172 1.0× | 23 | 1.4k | ||
| M.A. Christine Pratt Canada | 20 | 945 0.6× | 424 0.6× | 469 1.0× | 271 1.1× | 158 0.9× | 37 | 1.4k | ||
| Devon A. Thompson United States | 11 | 1.0k 0.7× | 450 0.6× | 377 0.8× | 176 0.7× | 100 0.6× | 12 | 1.6k | ||
| Francesco Trapasso Italy | 26 | 1.5k 1.0× | 330 0.4× | 375 0.8× | 312 1.3× | 344 1.9× | 74 | 2.0k | ||
| Ken C. N. Chang United States | 13 | 1.2k 0.8× | 740 1.0× | 469 1.0× | 391 1.6× | 133 0.7× | 21 | 1.8k |
Countries citing papers authored by Wenlin Shao
Since
Specialization
Citations
This map shows the geographic impact of Wenlin Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenlin Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenlin Shao more than expected).
Fields of papers citing papers by Wenlin Shao
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Wenlin Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenlin Shao. The network helps show where Wenlin Shao may publish in the future.
Co-authorship network of co-authors of Wenlin Shao
This figure shows the co-authorship network connecting the top 25 collaborators of Wenlin Shao. A scholar is included among the top collaborators of Wenlin Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenlin Shao. Wenlin Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schram, Alison M., Vivek Subbiah, Ryan J. Sullivan, et al.. (2023). Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors. Cancer Research. 83(8_Supplement). CT031–CT031.
2.
Schuller, Alwin G., Matt J. Griffin, Maryann San Martin, et al.. (2021). Abstract 1664: Inhibition of arginase in combination with radiation therapy shows increased immune-activation and anti-tumor activity in syngeneic tumor models. Cancer Research. 81(13_Supplement). 1664–1664.
3.
Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2020). Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood. 137(21). 2947–2957.
4.
Chandra, Dinesh, Christine M. Barbon, Alexandra Borodovsky, et al.. (2020). Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells. Cancer Immunology Research. 8(3_Supplement). A87–A87.
5.
Moorthy, Ganesh, Gayle P. Pouliot, Lorraine Graham, et al.. (2020). Abstract CT168: Clinical pharmacology of AZD4635 (A2ARi): Integration of PK data from cancer patients (CP) and healthy volunteer (HV) clinical trials to provide dosing recommendations. Cancer Research. 80(16_Supplement). CT168–CT168.
6.
Barbon, Christine M., Alexandra Borodovsky, Yanjun Wang, et al.. (2019). Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells. Cancer Research. 79(13_Supplement). LB–192.
7.
Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2019). Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models. Cancer Research. 79(13_Supplement). 2500–2500.
8.
Bendell, Johanna C., Todd M. Bauer, Manish R. Patel, et al.. (2019). Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Clinical Trials. CT026–CT026.
9.
Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2018). Abstract 306: A mechanistic rationale for combining acalabrutinib with CDK9 inhibitor, AZD4573, in ABC-DLBCL. Cancer Research. 78(13_Supplement). 306–306.
10.
Schoumacher, Marie, Kristen E. Hurov, Joseph Lehár, et al.. (2014). Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling. Cancer Research. 74(12). 3294–3305.
11.
Shultz, Michael D., Dyuti Majumdar, Donovan N. Chin, et al.. (2013). Structure–Efficiency Relationship of [1,2,4]Triazol-3-ylamines as Novel Nicotinamide Isosteres that Inhibit Tankyrases. Journal of Medicinal Chemistry. 56(17). 7049–7059.
12.
Whitehead, Lewis, Markus Dobler, Branko Radetich, et al.. (2011). Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorganic & Medicinal Chemistry. 19(15). 4626–4634.
13.
Cho, Young Shin, Lewis Whitehead, Jianke Li, et al.. (2010). Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824). Journal of Medicinal Chemistry. 53(7). 2952–2963.
14.
Shao, Wenlin, Joseph D. Growney, Yun Feng, et al.. (2010). Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistance. International Journal of Cancer. 127(9). 2199–2208.
15.
Durand, Mathieu, et al.. (2007). The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins. BMC Cell Biology. 8(1). 13–13.
16.
Carroll, Jason S., X. Shirley Liu, Alexander S. Brodsky, et al.. (2005). Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1. Cell. 122(1). 33–43.
17.
Anjos, Suzana M., Wenlin Shao, Luc Marchand, & Constantin Polychronakos. (2005). Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3′ +6230G>A polymorphism. Genes and Immunity. 6(4). 305–311.
18.
Shao, Wenlin, Erika Krasnickas Keeton, Donald P. McDonnell, & Myles Brown. (2004). Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proceedings of the National Academy of Sciences. 101(32). 11599–11604.
19.
Shao, Wenlin & Myles Brown. (2003). Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Research. 6(1). 39–52.
20.
Yahata, Tetsuro, Wenlin Shao, Hideki Endoh, et al.. (2001). Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes & Development. 15(19). 2598–2612.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Meei‐Huey Jeng Breakdown of academic impact, for papers by Erika Krasnickas Keeton Breakdown of academic impact, for papers by Cem Elbi Breakdown of academic impact, for papers by Jean-Marc Schlaeppi Breakdown of academic impact, for papers by Hema Parmar Breakdown of academic impact, for papers by M.A. Christine Pratt Breakdown of academic impact, for papers by Devon A. Thompson Breakdown of academic impact, for papers by Francesco Trapasso Breakdown of academic impact, for papers by Ken C. N. Chang